preclamol

centrally acting dopamine receptor agonist with selectivity for autoreceptors

Also Known As:

3-(3-hydroxyphenyl)-N-n-propylpiperidine; 3-PPP; n-N-propyl-3(N-hydroxyphenyl)piperidine; n-N-propyl-3-(3-hydroxyphenyl)piperidine; n-N-propyl-3-(3-hydroxyphenyl)piperidine, (+-)-isomer; n-N-propyl-3-(3-hydroxyphenyl)piperidine, R-(+)-isomer; n-N-propyl-3-(3-hydroxyphenyl)piperidine, S-(-)-isomer; Phenol, 3-(1-propyl-3-piperidinyl)-

Networked: 16 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - preclamol: 16

Related Diseases

1.	Dyskinesias (Dyskinesia) 01/01/1983 - "In the monkey with buccolingual dyskinesia all dyskinetic signs disappeared completely 2 hours after 2 mg/kg of 3-PPP. " 12/01/1993 - "Preclamol had a mild but unequivocal antiakinetic effect, less than that caused by subcutaneous apomorphine, but it provoked less dyskinesia. " 01/01/1988 - "Suppression of neuroleptic-induced persistent abnormal movements in Cebus apella monkeys by enantiomers of 3-PPP." 01/01/1988 - "The suppression of neuroleptic-induced persistent abnormal movements by 3-PPP enantiomers may be related to their ability to act as autoreceptor agonists, while the acute motor signs produced by higher doses of (+)-3-PPP may be due to activation of postsynaptic DA receptors. " 01/01/1983 - "Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias."
2.	Schizophrenia (Dementia Praecox) 01/01/1992 - "This study suggests that (-)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy."
3.	Catalepsy 01/01/1983 - "Two monkeys (1 choreic, 1 buccolingual) responded with dose-dependent symptom alleviation to 3-PPP, 1-4 mg/kg, with no signs of concomitant sedation or catalepsy. " 05/01/1987 - "However, raclopride is more potent than preclamol in suppressing treadmill locomotion, conditioned avoidance behaviour and catalepsy." 10/01/1993 - "Terguride (transdihydrolisuride), a partial DA receptor agonist with an efficacy lower than that of preclamol, blocked haloperidol (10.6 mumol/kg, i.p.) induced catalepsy at 5 mumol/kg, s.c., but not at 20 mumol/kg, s.c. " 05/01/1987 - "Effects of raclopride on exploratory locomotor activity, treadmill locomotion, conditioned avoidance behaviour and catalepsy in rats: behavioural profile comparisons between raclopride, haloperidol and preclamol." 10/01/1993 - "The partial DA receptor agonist preclamol, (-)-3-PPP (50-200 mumol/kg, s.c.) partially reversed the catalepsy induced by the dopamine (DA) receptor antagonists haloperidol (5.3 mumol/kg, i.p.) and raclopride (20.1 mumol/kg, i.p.) in rats. "
4.	Vomiting 04/16/1984 - "In contrast SCH 23390 has no effect on apomorphine-induced vomiting in dogs and little effects on 6-OHDA-denervated supersensitive DA receptors, stimulated by the DA agonist 3-PPP. "
5.	Seizures (Absence Seizure) 05/01/1995 - "2. (+) 3-PPP dose-dependently (60-100 mg/kg i.p.) produced behavioural and electrical tonic-clonic seizures. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Haloperidol (Haldol)
3.	Dopamine (Intropin)
4.	Autoreceptors
5.	piperidine
6.	Apomorphine
7.	Raclopride
8.	Dopamine Agonists (Dopamine Agonist)
9.	dironyl (terguride)
10.	Quinpirole